Study of immune weakness in adults with blood cancer in Kazakhstan
This study looks at adults in Kazakhstan with blood cancers whose immune systems are weakened, causing frequent or severe infections. It aims to understand how common this is and may help improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with a blood cancer such as multiple myeloma, chronic lymphocytic leukemia, non-Hodgkin lymphoma, acute leukemia, or a myeloproliferative neoplasm.
- Your medical records are available for review during the study period.
- You have a weakened immune system, shown by low antibody levels, poor response to vaccines, or a history of frequent or severe infections (like 3 or more infections a year needing antibiotics, pneumonia, sepsis, or infections requiring hospital care).
- You do not have a primary immunodeficiency (a genetic immune disorder).
- You have not been in another drug or device trial during the study period.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a smartphone or web app to track infections and quality of life in people with multiple myeloma or chronic lymphocytic leukemia who have a weakened immune system. The goal is to create a better screening tool for infections and understand how the disease and treatment affect daily life.
This study collects blood (and sometimes related samples) to learn how genes and the immune system work in people with primary immunodeficiency (PID) or in family members who may not have it. The goal is to improve understanding of rare immune conditions and help guide future care.
This study looks at how well immunoglobulin replacement therapy works in people with low antibody levels and how it affects the immune system. It aims to help improve treatment for primary antibody immunodeficiencies.
This study looks at blood or tissue samples from people with certain genetic disorders that affect a key cell communication pathway (JAK-STAT). The goal is to learn more about these disorders and test potential treatments in the lab.
This trial tests a new medicine (BP-SCIG 20%) given under the skin to help children and adults with primary immunodeficiency who have trouble making antibodies. It aims to see if the medicine is safe and works well to prevent infections.
This study is for adults whose immune system has trouble fighting viruses due to specific antibodies or a genetic condition. Researchers want to follow these people over time to better understand the condition and improve care.
Hear when a new Secondary Immunodeficiency (SID) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.